CA3120973A1 - Methods of treating myeloproliferative disorders - Google Patents
Methods of treating myeloproliferative disorders Download PDFInfo
- Publication number
- CA3120973A1 CA3120973A1 CA3120973A CA3120973A CA3120973A1 CA 3120973 A1 CA3120973 A1 CA 3120973A1 CA 3120973 A CA3120973 A CA 3120973A CA 3120973 A CA3120973 A CA 3120973A CA 3120973 A1 CA3120973 A1 CA 3120973A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- ruxolitinib
- day
- isoxazolo
- azepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 53
- 208000014767 Myeloproliferative disease Diseases 0.000 title description 4
- 206010028537 myelofibrosis Diseases 0.000 claims abstract description 48
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 63
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 63
- 229960000215 ruxolitinib Drugs 0.000 claims description 63
- 238000011282 treatment Methods 0.000 claims description 55
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 48
- 210000004369 blood Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 31
- 108010054147 Hemoglobins Proteins 0.000 claims description 27
- 102000001554 Hemoglobins Human genes 0.000 claims description 27
- 108010024121 Janus Kinases Proteins 0.000 claims description 20
- 102000015617 Janus Kinases Human genes 0.000 claims description 20
- 208000007502 anemia Diseases 0.000 claims description 19
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 16
- 230000001419 dependent effect Effects 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 10
- 210000000440 neutrophil Anatomy 0.000 claims description 9
- 206010016256 fatigue Diseases 0.000 claims description 8
- 208000000059 Dyspnea Diseases 0.000 claims description 7
- 206010013975 Dyspnoeas Diseases 0.000 claims description 7
- 206010059186 Early satiety Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 206010029410 night sweats Diseases 0.000 claims description 7
- 230000036565 night sweats Effects 0.000 claims description 7
- 206010041660 Splenomegaly Diseases 0.000 claims description 6
- 208000002173 dizziness Diseases 0.000 claims description 5
- 206010006002 Bone pain Diseases 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
- 206010000059 abdominal discomfort Diseases 0.000 claims description 4
- 206010022437 insomnia Diseases 0.000 claims description 4
- 206010019842 Hepatomegaly Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 230000003582 thrombocytopenic effect Effects 0.000 claims description 3
- GCWIQUVXWZWCLE-INIZCTEOSA-N pelabresib Chemical compound N([C@@H](CC(N)=O)C=1ON=C(C=1C1=CC=CC=C11)C)=C1C1=CC=C(Cl)C=C1 GCWIQUVXWZWCLE-INIZCTEOSA-N 0.000 abstract description 5
- 229940125904 compound 1 Drugs 0.000 description 56
- 210000001772 blood platelet Anatomy 0.000 description 38
- 210000003593 megakaryocyte Anatomy 0.000 description 24
- 208000024891 symptom Diseases 0.000 description 24
- 210000000952 spleen Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- 230000004069 differentiation Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 238000009097 single-agent therapy Methods 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 238000002559 palpation Methods 0.000 description 7
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 6
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 6
- 208000003476 primary myelofibrosis Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 4
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 4
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 4
- 108091058560 IL8 Proteins 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 4
- 208000005485 Thrombocytosis Diseases 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- -1 inhalants Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010033661 Pancytopenia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 208000024389 cytopenia Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960004942 lenalidomide Drugs 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 230000000610 leukopenic effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002206 pro-fibrotic effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 229940045759 ruxolitinib 15 mg Drugs 0.000 description 2
- 229940045783 ruxolitinib 5 mg Drugs 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108050009021 Bromodomains Proteins 0.000 description 1
- 102000001805 Bromodomains Human genes 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 108010074604 Epoetin Alfa Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000659879 Homo sapiens Thrombospondin-1 Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102100036034 Thrombospondin-1 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 101710112793 Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 101710112791 Tyrosine-protein kinase JAK2 Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000009218 additive inhibitory effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940125763 bromodomain inhibitor Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229950004291 imetelstat Drugs 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229950001890 itacitinib Drugs 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940045807 ruxolitinib 10 mg Drugs 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2018/062534 WO2020112086A1 (en) | 2018-11-27 | 2018-11-27 | Methods of treating myeloproliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3120973A1 true CA3120973A1 (en) | 2020-06-04 |
Family
ID=64734125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3120973A Pending CA3120973A1 (en) | 2018-11-27 | 2018-11-27 | Methods of treating myeloproliferative disorders |
Country Status (8)
| Country | Link |
|---|---|
| JP (2) | JP7453230B2 (enExample) |
| KR (2) | KR20250004357A (enExample) |
| AU (1) | AU2018451360B2 (enExample) |
| BR (1) | BR112021010134A2 (enExample) |
| CA (1) | CA3120973A1 (enExample) |
| EA (1) | EA202191489A1 (enExample) |
| SG (1) | SG11202105279SA (enExample) |
| WO (1) | WO2020112086A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021006205A (es) | 2018-11-27 | 2021-10-13 | Constellation Pharmaceuticals Inc | Metodos de tratamiento de trastornos mieloproliferativos. |
| JP2022549506A (ja) | 2019-09-27 | 2022-11-25 | ディスク・メディシン・インコーポレイテッド | 骨髄線維症および関連状態を処置するための方法 |
| EP4149548A4 (en) | 2020-05-13 | 2024-05-08 | Disc Medicine, Inc. | ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS |
| MX2023001552A (es) * | 2020-08-04 | 2023-05-03 | Constellation Pharmaceuticals Inc | 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c]isoxazolo[4,5-e]azepi n-4- il)acetamida para tratar trombocitemia. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
| HUE043441T2 (hu) | 2014-06-20 | 2019-08-28 | Constellation Pharmaceuticals Inc | 2-((4S)-6-(4-klórfenil)-l-metil-4H-benzo[c]izoxazolo[4,5-e]azepin-4-il)acetamid kristályos formái |
-
2018
- 2018-11-27 WO PCT/US2018/062534 patent/WO2020112086A1/en not_active Ceased
- 2018-11-27 KR KR1020247040010A patent/KR20250004357A/ko active Pending
- 2018-11-27 CA CA3120973A patent/CA3120973A1/en active Pending
- 2018-11-27 SG SG11202105279SA patent/SG11202105279SA/en unknown
- 2018-11-27 JP JP2021530108A patent/JP7453230B2/ja active Active
- 2018-11-27 EA EA202191489A patent/EA202191489A1/ru unknown
- 2018-11-27 AU AU2018451360A patent/AU2018451360B2/en active Active
- 2018-11-27 KR KR1020217019508A patent/KR102738936B1/ko active Active
- 2018-11-27 BR BR112021010134-9A patent/BR112021010134A2/pt unknown
-
2024
- 2024-03-07 JP JP2024034717A patent/JP2024063214A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018451360B2 (en) | 2022-05-26 |
| WO2020112086A1 (en) | 2020-06-04 |
| SG11202105279SA (en) | 2021-06-29 |
| KR20210095904A (ko) | 2021-08-03 |
| KR102738936B1 (ko) | 2024-12-06 |
| KR20250004357A (ko) | 2025-01-07 |
| JP2022519425A (ja) | 2022-03-24 |
| EA202191489A1 (ru) | 2021-09-10 |
| BR112021010134A2 (pt) | 2021-08-24 |
| AU2018451360A1 (en) | 2021-06-10 |
| JP2024063214A (ja) | 2024-05-10 |
| JP7453230B2 (ja) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12070464B2 (en) | Methods of treating myeloproliferative disorders | |
| JP2024063214A (ja) | 骨髄増殖性障害を治療する方法 | |
| JP5936628B2 (ja) | ｍＴＯＲ／ＪＡＫ阻害剤併用療法 | |
| US20220168333A1 (en) | Combination Treatment for Hematological Cancers | |
| MX2012014416A (es) | Tratamiento de cancer de sangre. | |
| KR20180124055A (ko) | 급성 골수성 백혈병의 치료를 위한 병용 요법 | |
| JP2021119162A (ja) | 肝疾患の予防および治療のための薬物の調製におけるトリメタジジンの使用 | |
| WO2021091532A1 (en) | Methods of treating myeloproliferative disorders | |
| WO2020256739A1 (en) | Methods of treating myeloproliferative disorders | |
| KR20230110751A (ko) | 골수섬유증의 치료에 사용하기 위한 cxcr1/cxcr2 억제제 | |
| EA047870B1 (ru) | Способы лечения миелопролиферативных расстройств | |
| EP4337213A1 (en) | Use of pelabresib for treating anemias | |
| US20250154243A1 (en) | Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations | |
| WO2025096692A2 (en) | Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations | |
| WO2025002346A1 (zh) | 含pd-l1小分子抑制剂的药物组合及其应用 | |
| TW202432141A (zh) | 治療骨髓增生性腫瘤的方法 | |
| JP2025523114A (ja) | Ａｔリッチ相互作用ドメイン含有タンパク質１ａ（ａｒｉｄ１ａ）突然変異癌を処置するためのｅｚｈ２阻害療法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220812 |
|
| EEER | Examination request |
Effective date: 20220812 |
|
| EEER | Examination request |
Effective date: 20220812 |
|
| EEER | Examination request |
Effective date: 20220812 |
|
| EEER | Examination request |
Effective date: 20220812 |